Wedbush Downgrades Design Therapeutics to Neutral, Announces $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Laura Chico has downgraded Design Therapeutics (NASDAQ:DSGN) from Outperform to Neutral and set a price target of $6.
August 15, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Design Therapeutics has been downgraded from Outperform to Neutral by Wedbush, with a new price target of $6.
The downgrade from Outperform to Neutral by Wedbush indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $6 also suggests a lower valuation for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100